A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis

Journal of Managed Care Pharmacy

Volumn 16, Issue 1, 2010, Pages 46-58

  Frogel, Michael P ^a   Stewart, Dan L ^b   Hoopes, Michael ^c   Fernandes, Ancilla W ^d   Mahadevia, Parthiv J ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b KOSAIR CHILDREN'S HOSPITAL   (United States)

^c Medical Information ^*  (China)

^d Health Outcomes and Pharmacoeconomics MedImmune   (United States)

^e MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

BIRTH; CLINICAL TRIAL; CULTURAL FACTOR; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG UTILIZATION; HEALTH PROGRAM; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; LANGUAGE ABILITY; LOWER RESPIRATORY TRACT INFECTION; MEDICAID; PARENT; PARENT COUNSELING; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACY; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK FACTOR; SEASONAL VARIATION; SYSTEMATIC REVIEW; TELEPHONE; TRAFFIC AND TRANSPORT; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL BRONCHIOLITIS; VIRUS INFECTION; VIRUS PNEUMONIA;

EID: 76549131273     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.1.46     Document Type: Review

References (60)

1. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-32.
2. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002;21(7):629-32.
3. Centers for Disease Control and Prevention (CDC). Bronchiolitis- associated outpatient visits and hospitalizations among American Indian and Alaska Native children-United States, 1990-2000. Morb Mortal Wkly Report. 2003;52(30):707-10. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5230a5. htm. Accessed December 4, 2009.
4. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440- 46. Available at: http://jama.ama-assn.org/cgi/reprint/282/15/1440. Accessed October 30, 2009.
5. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-86. Available at: http://jama.ama-assn.org/cgi/content/full/289/ 2/179. Accessed December 4, 2009.
6. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126(2):212-19.
7. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121(3):348-54.
8. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004;22(5):275-84.
9. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307(7):397-400.
10. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815-20.
11. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Inject Dis J. 2004;23(9):806-14.
12. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J. 2000;19(7):592-97.
13. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-93. Available at: http://pediatrics.aappublications.org/cgi/ reprint/118/4/1774. Accessed December 4, 2009.
14. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5 Suppl):S133-41.
15. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 Pt l):419-27.
16. Robbins JM, Tilford JM, Jacobs RF, et al. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152(4):358-66. Available at: http://archpedi.ama-assn.org/cgi/reprint/152/4/358.pdf. Accessed December 4, 2009.
17. Forbes ML, Hall CB, Jackson A, et al. Cost and resource utilization of respiratory syncytial virus (RSV) or winter unspecified bronchiolitis or pneumonia (UBP) hospitalizations during the first year of life among late-preterm and full-term infants. Poster presented at: ISPOR 14th Annual International Meeting; May 16-20, 2009; Orlando, FL.
18. Pérez-Yarza EG, Moreno A, Lázaro P, et al. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Inject Dis J. 2007;26(8):733-39.
19. Synagis (palivizumab). Full prescribing information. Medlmmune, LLC; Gaithersburg, MD: 2008. Available at: http://www.medimmune.com/pdf/products/ synagis-pi.pdf. Accessed December 4, 2009.
20. Mullins JA, LaMonte AC, Bresee JS, Anderson LJ. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J. 2003;22(10):857-62.
21. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531-37.
22. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-40.
23. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-17.
24. Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the Palivizumab Outcomes Registry. Pediatr Pulmonol 2003;35(6):484-89.
25. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Inject Dis J. 2003;22(2 Suppl):S46-54.
26. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000;19(11):1068-71.
27. Cohen SA, Zanni R, Cohen A, et al. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol. 2007;29(2):382-87.
28. Cohen AH, Sorrentino M, Powers T. Effectiveness of palivizumab for preventing serious RSV disease. J Resp Dis. 2000;2(Suppl):S30-32.
29. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22(9):823-87.
30. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211-16.
31. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red Book 2003 Report of the Committee on lnjectious Diseases. 26th edition. Elk Grove Village, IL: American Academy of Pediatrics; 2003:523-28.
32. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):169-701. Available at: http://pediatrics.aappublications.org/cgi/ reprint/peds.2009-2345vl. Accessed December 4, 2009.
33. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-19.
34. BlueCross BlueShield of Illinois. Prior Authorization: Synagis (palivizumab). Available at: http://www.bcbsil.com/provider/pdf/synagis.pdf. Accessed December 4, 2009.
35. Hughes S, Springer L, Kehoe K. Multiple treatment sites effect on RSV prophylaxis compliance [abstract P1312E]. Poster presented at: 39th Annual Meeting of the American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibits; December 5-9, 2004; Orlando, FL.
36. Chua CO, Mercado VV, Golombek SG. Compliance with palivizumab prophylaxis for respiratory syncytial virus in a home-care based program [abstract 253]. Poster presented at: 118th Annual Meeting of the American Pediatric Society/77th Annual Meeting for the Society for Pediatric Research; May 3, 2008; Honolulu, HI.
37. Chua CO, Mercado VV, Siegel M, et al. Compliance with RSV prophylaxis: a comparison between office and home settings [abstract 160775]. Poster presented at: 135th Annual Meeting and Exposition of the American Public Health Association (APHA); November 3-7, 2007; Washington, DC.
38. Srinivasan G, Srinivasan HB. Compliance with RSV prophylaxis in an urban inner-city population [abstract 6280.9). Poster presented at: 117th Annual Meeting of the American Pediatric Society/76th Annual Meeting for the Society for Pediatric Research and the 2007 Annual Meeting of the American Society of Pediatric Hematology/Oncology; May 3-6, 2007; Toronto, Canada.
39. Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J. 2008;27(2):175-76.
40. Roberts JR, Martines J, White S, et al. Improving compliance for respiratory syncytial virus prophylaxis [abstract 279]. Poster presented at: Southern Regional Meeting of the American Federation for Medical Research; March 3-5, 2006; Atlanta, GA.
41. Blais LR, Williams LB, Lamoureux VA. A novel home-care based program for palivizumab prophylaxis reduces RSV hospitalizations [abstract 3343]. Poster presented at: 114th Annual Meeting of the American Pediatric Society/73rd Annual Meeting of the Society for Pediatric Research; May 1, 2004; San Francisco, CA.
42. Pignotti MS, Indolfi G, Donzelli G. Factors impacting compliance with palivizumab prophylaxis. Pediatr Inject Dis J. 2004;23(2):186-87.
43. Paul DA, Leef KH, Chidekel A, et al. Home delivery of palivizumab: outcomes and compliance in regional preterm infants. Del Med J. 2002;74(1):11-15.
44. Frogel MP, Nerwen C, Boron M, et al. Impact of Medicaid insurance status among 19,474 infants given RSV monoclonal antibody prophylaxis [abstract 889]. Poster presented at: 115th Annual Meeting of the American Pediatric Society and 74th Annual Meeting of the Society for Pediatric Research together with the American Society of Pediatric Hematology/Oncology, the American Society of Pediatric Nephrology, the Lawson Wilkins Pediatric Endocrine Society, and the Pediatric Infectious Disease Society; May 14-17, 2005; Washington, DC.
45. Romero J, Cohen A, Boron M, et al. Respiratory syncytial virus (RSV) prophylaxis in minority populations; results from the Palivizumab Outcomes Registry 2002-2003 [abstract 1344]. Poster presented at: 114th Annual Meeting of the American Pediatric Society/73rd Annual Meeting of the Society for Pediatric Research; May 1-4, 2004; San Francisco, CA.
46. Gelfandl A, Cohen A, Boron M, Rankin M. RSV prophylaxis in African American children; results from the Palivizumab Outcomes Registry 2002-2003 [abstract 2944]. Poster presented at: 100th International Conference of the American Thoracic Society; May 21-24, 2004; Orlando, FL.
47. Macagno F; Previeni (Prevenzione del Virus respiratorio sinciziale: Epidemiologica Nazionale Italiana) Investigators. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection. Pediatr Med Chir. 2005;27(3-4):70-77.
48. Macagno F. Previeni (Prevenzione del Virus respiratorio sinciziale: Epidemiologica Nazionale Italiana) Investigators. Compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection: results of the second season of the Previeni Study. Ped Med Chir. 2005;27(3-4):78-87.
49. Frogel MP, Nerwen C. Six year experience with a coordinated neonatal and general pediatric practice palivizumab program that increases compliance and prevents RSV hospitalizations of high-risk infants [abstract 3128]. Poster presented at: 115th Annual Meeting of the American Pediatric Society and 74th Annual Meeting of the Society for Pediatric Research together with the American Society of Pediatric Hematology/Oncology, the American Society of Pediatric Nephrology, the Lawson Wilkins Pediatric Endocrine Society, and the Pediatric Infectious Disease Society; May 14, 2005; Washington, DC.
50. Awaida L, Roupret J, Prot-Labarthe S, et al. Evaluation of palivizumab compliance in paediatric patients and impact of patient education: a two year experience [abstract EDU-222]. Poster presented at: European Society of Clinical Pharmacy 5th Spring Conference on Clinical Pharmacy: Integrating Research, Education and Clinical Practice; May 25-28, 2005; Stockholm, Sweden.
51. Golombek SG, Berning K, Berning F. Benefits of an in-home palivizumab prophylaxis program: Three-year results. Pediatr Res. 2004;55(Suppl S, Pt 24):542A. Poster presented at: 114th Annual Meeting of the American Pediatric Society/73rd Annual Meeting of the Society for Pediatric Research; May 1-4, 2004; San Francisco, CA.
52. Singleton RJ, Bruden D, Brooks L, et al. Closer to home: Local care improves compliance with RSV prophylaxis in high-risk infants. Int J Circumpolar Health. 2006;65(1):4-7.
53. Langkamp DL, Hlavin SM. Factors predicting compliance with palivizumab in high-risk infants. Am J Perinatol. 2001;18(6):345-52.
54. Langkamp DL, Hlavin SM. Improving compliance with palivizumab. Pediatr Res, 2002;51(4 Pt 2):297A. Poster presented at: American Pediatric Society/Society for Pediatric Research Annual Meeting; May 4-7, 2002; Baltimore, MD.
55. Langkamp DL, Hlavin SM, Bowen M. Compliance with palivizumab. Pediatr Res. 2001;49(4 Pt 2):238A. Poster presented at: American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association Annual Meeting; April 27-May 1, 2001; Baltimore, MD.
56. Pignotti MS, Catarzi S, Donzelli G. A 4-year survey on palivizumab respiratory syncytial virus (RSV) prophylaxis: How can compliance be improved? J Matern Fetal Neonatal Med. 2006;19(4):221-24.
57. Berger J, Fensterheim L, O'Rourke J, et al. The importance of Synagis compliance in preventing hospitalizations [abstract]. Pediatr Res. 2003;53(4 Pt 2):468A-9.
58. Mitchell I, Xu J, Johnson D, et al. Compliance study on respiratory syncytial virus (RSV) prevention program [abstract 4745]. Poster presented at: 100th International Conference of the American Thoracic Society; May 21-26, 2004; Orlando, FL.
59. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Inject Dis. 2000;31(2):590-96.
60. Suchanek D. The rise and role of specialty pharmacy. Biotechnology Healthcare. October 2005. Alliance for Health Reform. Available at: http://www.allhealth.org/BriefingMaterials/BiotechHealthcareSpecialtyPharmacies- 416.pdf. Accessed December 5, 2009.